SKB105 + CR-003

SKB105 + CR-003 refers to a combination involving the antibody-drug conjugate (ADC) targeting Protein Tyrosine Kinase 7 (PTK7), where SKB105 is the original code name from Sichuan Kelun-Biotech and CR-003 is the designation used by Crescent Biopharma. As these two names refer to the same therapeutic agent, the combination effectively describes the single ADC product. This PTK7-targeted ADC is designed to deliver a cytotoxic payload, typically a topoisomerase I inhibitor, directly to tumor cells overexpressing PTK7, a protein associated with cancer stemness and poor prognosis in various solid tumors. Under a strategic partnership established in late 2024/2025, Crescent Biopharma licensed the rights to develop this ADC, often exploring its potential in combination with other agents like the PD-1 x VEGF bispecific antibody CR-001 (SKB571).

Other names

SKB105SKB-105SKB 105CR-003CR003CR 003